

#7

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
	APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 5, 2001	GROUP 1646

1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
Amz	5,843,780	12/01/98	Thomson	435	363	01/18/96
Amz	6,153,591	11/28/00	Cai et al.	514	19	03/16/99
Amz	6,200,969	03/13/01	Fritz et al.	514	214	09/12/97

FOREIGN PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANS- LATION YES/NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

Amz	GenBank Accession No.: NM_005587 - Homo sapiens MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) (MEF2A) mRNA.
↓	GenBank Accession No.: NM_005919 - Homo sapiens MADS box transcription enhancer factor 2, polypeptide B (myocyte enhancer factor 2B) (MEF2B) mRNA.
Amz	GenBank Accession No.: L08895 - Homo sapiens MADS/MEF2-family transcription factor (MEF2C) mRNA, complete cds.

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED 4/3/03
------------------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1446 PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
		APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 5, 2001	GROUP: 1646

1632

Am2	GenBank Accession No.: NM_005920 - Homo sapiens MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D) (MEF2D) mRNA.
	Arsenijevic and Weiss, "Insulin-Like Growth Factor-I Is a Differentiation Factor for Postmitotic CNS Stem Cell-Derived Neuronal Precursors: Distinct Actions from Those of Brain-Derived Neurotrophic Factor," <u>Journal of Neuroscience</u> 18:2118-2128 (1998)
	Bain et al., "From Embryonal Carcinoma Cells to Neurons: The P19 Pathway," <u>Bioessays</u> 16:343-348 (1994)
	Bain et al., "Embryonic Stem Cells Express Neuronal Properties in Vitro," <u>Developmental Biology</u> 168:342-357 (1995)
	Bhatia et al., "A newly discovered class of human hematopoietic cells with SCID-repopulating activity," <u>Nature Medicine</u> 4:1038-1045 (1998)
	Black et al., "Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family," <u>J. Biol. Chem.</u> 271:26659-26663 (1996)
	Black and Olson, "Transcriptional Control of Muscle Development by Myocyte Enhancer Factor-2 (MEF2) Proteins," <u>Annual Rev. Cell Dev. Biol.</u> 14:167-196 (1998)
↓	Blaschke et al., "Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex," <u>Development</u> 122:1165-1174 (1996)
Am2	Brand, "Molecules in Focus," <u>Int. J. Biochem. Cell Biol.</u> 29:1467-1470 (1997)

EXAMINER <i>Anne-Marie Jalk</i>	DATE CONSIDERED 4/3/03
------------------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
		APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 5, 2001	GROSS 1646

1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Ama	Breitbart et al., "A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage," <u>Development</u> 118:1095-1106 (1993)
	Brooker et al., "Endogenous IGF-1 Regulates the neuronal Differentiation of Adult Stem Cells," <u>J. Neurosci. Res.</u> 59:332-341 (2000)
	Clem et al., "Prevention of apoptosis by a baculovirus gene during infection of insect cells," <u>Science</u> 254:1388-1390 (1991)
	D'Amour and Gage, "New tools for human developmental biology," <u>Nature Biotechnology</u> 18:381-382 (2000)
	Deveraux and Reed, "IAP family proteins - suppressors of apoptosis," <u>Genes & Development</u> 13:239-252 (1999)
	Dunnett et al., "Neuronal cell transplantation for Parkinson's and Huntington's diseases," <u>British Medical Bulletin</u> 53:757-776 (1997)
	Ekert et al., "Caspase Inhibitors," <u>Cell Death and Differentiation</u> 6:1081-1086 (1999)
	English et al., "Contribution of the ERK5/MEK5 Pathway to Ras/Raf Signaling and Growth Control," <u>J. Biol. Chem.</u> 274:31588-31592 (1999)
↓	Fujimoto et al., "Identification of genes differentially expressed by putrescine in HepG2 hepatoblastoma cells," <u>Hepatology Research</u> 20:207-215 (2001)
Ama	Galpern, et al., "Xenotransplantation of porcine fetal ventral mesencephalon in rat model of Parkinson's disease: Functional recovery and graft morphology," <u>Exp. Neurol.</u> 140:1-13 (1996)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED <i>4/3/03</i>
------------------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
		APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 5, 2001	GROUP: 1646 1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Am2	Garcia-Calvo et al., "Inhibition of Human Caspases by Peptide-based and Macromolecular Inhibitors," <u>J. Biol. Chem.</u> 273:32608-32613 (1998)
	Ghosh and Greenberg, "Distinct Roles for bFGF and NT-3 in the Regulation of Cortical Neurogenesis," <u>Neuron</u> 15:89-103 (1995)
	Ghosh et al., "Requirement for BDNF in Activity-Dependent Survival of Cortical Neurons," <u>Science</u> 263:1618-1623 (1994)
	Han et al., "Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation," <u>Nature</u> 386:296-299 (1997)
	Jacks et al., "Effects of an Rb mutation in the mouse," <u>Nature</u> 359:295-300 (1992)
	Jan and Jan, "HLH proteins, fly neurogenesis, and vertebrate myogenesis," <u>Cell</u> 75:827-830 (1993)
	Jo et al., "Differential display analysis of gene expression altered by ras oncogene," <u>Methods Enzymol.</u> 332:233-244 (2001)
	Johe et al., "Single factors direct the differentiation of stem cells from the fetal and adult central nervous system," <u>Genes and Development</u> 10:3129-3140 (1996)
	Kato et al., "BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C," <u>EMBO J.</u> 16:7054-7066 (1997)
↓	Kato et al., "Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor," <u>Nature</u> 395:713-716 (1998)
Am2	Kaushal et al., "Activation of the myogenic lineage by MEF2A, a factor that induces and cooperates with MyoD," <u>Science</u> 266:1236-1240 (1994)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED 4/3/03
------------------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 PATENT & TRADEMARK	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
		APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 5, 2001	GROUP: 1646 1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Am2	Khanna et al., "Metastasis-associated differences in gene expression in a murine model of osteosarcoma," <u>Cancer Res.</u> 61:3750-3759 (2001)
	Kuida et al., "Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice," <u>Nature</u> 384:368-372 (1996)
	Lee et al., "Gene expression profile of aging and its retardation by caloric restriction," <u>Science</u> 285:1390-1393 (1999)
	Lee et al., "Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7 Inhibit Apoptosis and Maintain Cell Functionality," <u>J. Biol. Chem.</u> 275:16007-16014 (2000)
	Lee et al., "Myocyte-specific enhancer factor 2 and thyroid hormone receptor associate and synergistically activate the α -cardiac myosin heavy-chain gene," <u>Mol. Cell. Biol.</u> 17:2745-2755 (1997)
	Lee, "Basic helix-loop-helix genes in neural development," <u>Current Opinion in Neurobiology</u> 7:13-20 (1997)
	Leifer et al., "MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex," <u>Proc. Natl. Acad. Sci. USA</u> 90:1546-1550 (1993)
	Leifer et al., "Myocyte-specific enhancer binding factor 2C expression in human brain development," <u>Neuroscience</u> 63:1067-1079 (1994)
Am2	Lilly et al., "Requirement of MADS domain transcription factor D-MEF2 for muscle formation in <i>Drosophila</i> ," <u>Science</u> 267:688-693 (1995)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED <i>4/3/03</i>
------------------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 PATENT & TRADEMARK OFFICE	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
		APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 5, 2001	GROUP: 1646 1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Am2		Lilly et al., "D-MEF2: a MADS box transcription factor expressed in differentiating mesoderm and muscle cell lineages during <i>Drosophila</i> embryogenesis," <u>Proc. Natl. Acad. Sci. USA</u> 91:5662-5666 (1994)
		Lin et al., "The expression of MEF2 genes is implicated in CNS neuronal differentiation," <u>Mol. Brain. Res.</u> 42:307-316 (1996)
		Lin et al., "Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C," <u>Science</u> 276:1404-1407 (1997)
		Lipton and Rosenberg, "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders," <u>New England Journal of Medicine</u> 330:613-622 (1994)
		Lu et al., "Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases," <u>Proc. Natl. Acad. Sci., USA</u> 97:4070-4075 (2000)
		Lyons et al., "Expression of <i>mef2</i> genes in the mouse central nervous system suggests a role in neuronal maturation," <u>J. Neurosci.</u> 15:5727-5738 (1995)
		Mao and Nadal-Ginard, "Functional and physical interactions between mammalian achaete-scute homolog 1 and myocyte enhancer factor 2A," <u>J. Biol. Chem.</u> 271:14371-14375 (1996)
	✓	Mao et al., "Neuronal Activity-Dependent Cell Survival Mediated by Transcription Factor MEF2," <u>Science</u> 286:785-790 (1999)
Am2		Martin et al., "Myocyte enhancer factor (MEF) 2C: A tissue-restricted member of the MEF-2 family of transcription factors," <u>Proc. Natl. Acad. Sci. USA</u> 90:5282-5286 (1993)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED 4/3/03
------------------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
	APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 5, 2001	GROUP: 1646 1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Ama	•	Martin et al., "A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing," <u>Mol. Cell. Biol.</u> 14:1647-1656 (1994)
↓	•	Matsumoto et al., "Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration," <u>J. Biol. Chem.</u> 274:13954-13960 (1999)
↓	•	McBurney, "P19 embryonal carcinoma cells," <u>Int. J. Dev. Biol.</u> 37:135-140 (1993)
↓	•	McDermott et al., "hMEF2C gene encodes skeletal muscle- and brain-specific transcription factors," <u>Mol. Cell. Biol.</u> 13:2564-2577 (1993)
↓	•	McDonald et al., "Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord," <u>Nature Medicine</u> 5:1410-1412 (1999)
↓	•	Mezey et al., "Turning Blood into Brain: Cells Bearing Neuronal Antigens Generated in Vivo from Bone Marrow," <u>Science</u> 290:1779-1782 (2000)
↓	•	Miraglia et al., "A Novel Five-Transmembrane Hematopoietic Stem Cell Antigen: Isolation, Characterization, and Molecular Cloning," <u>Blood</u> 90:5013-5021 (1997)
↓	•	Miyoshi et al., "Transduction of Human CD34+ Cells That Mediate Long-Term Engraftment of NOD/SCID Mice by HIV Vectors," <u>Science</u> 283:682-686 (1999)
Ama	•	Molkentin et al., "Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins," <u>Cell</u> 83:1125-1136 (1995)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED 4/3/03
------------------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
	APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 5, 2001	GROUP: 1646 1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Ama	•	Molkentin et al., "MEF2B Is a Potent Transactivator Expressed in Early Myogenic Lineages," <u>Mol. Cell. Biol.</u> 16:3814-3824 (1996)
	•	Molkentin et al., "Mutational analysis of the DNA binding, dimerization, and transcriptional activation domains of MEF2C," <u>Mol. Cell. Biol.</u> 16:2627-2636 (1996)
	•	Mukasa et al., "Wortmannin enhances CPP32-like activity during neuronal differentiation of P19 embryonal carcinoma cells induced by retinoic acid," <u>Biochem. Biophys. Res. Commun.</u> 232:192-197 (1997)
	•	Naya and Olson, "MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation," <u>Current Opinion in Cell Biology</u> 11:683-688 (1999)
	•	New and Han, "The p38 MAP Kinase Pathway and Its Biological Function," <u>Trends Cardiovasc. Med.</u> 8:220-229 (1998)
	•	Nguyen et al., "D-mef2: a <i>Drosophila</i> mesoderm-specific MADS box-containing gene with a biphasic expression profile during embryogenesis," <u>Proc. Natl. Acad. Sci. USA</u> 91:7520-7524 (1994)
	•	Nicholson, "From bench to clinic with apoptosis-based therapeutic agents," <u>Nature</u> 407:810-816 (2000)
	•	Okamoto et al., "Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation," <u>Proc. Natl. Acad. Sci., USA</u> 97:7561-7566 (2000)
Ama	•	Olson et al., "Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors," <u>Dev. Biol.</u> 172:2-14 (1995)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED <i>4/3/03</i>
------------------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	PATENT DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,187
	APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 5, 2001	GROUP: 1646 1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Ama	Ornatsky et al., "A dominant-negative form of transcription factor MEF2 inhibits myogenesis," <u>J. Biol. Chem.</u> 272:33271-33278 (1997)
	Pollock and Triesman, "Human SRF-related proteins: DNA-binding properties and potential regulatory targets," <u>Genes & Dev.</u> 5:2327-2341 (1991)
	Reubinoff et al., "Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro," <u>Nature Biotechnology</u> 18:399-404 (2000)
	Robert et al., "Differential display and suppressive subtractive hybridization used to identify granulosa cell messenger RNA associated with bovine oocyte developmental competence," <u>Biol. Reprod.</u> 64:1812-1820 (2001)
	Skerjanc and Wilton, "Myocyte enhancer factor 2C upregulates MASH-1 expression and induces neurogenesis in P19 cells," <u>FEBS Letters</u> 472:53-56 (2000)
	Slack et al., "Cells differentiating into neuroectoderm undergo apoptosis in the absence of functional retinoblastoma family proteins," <u>J. Cell Biol.</u> 129:779-788 (1995)
	Staeger et al., "Two novel genes <i>FIND</i> and <i>LIND</i> differentially expressed in deactivated and <i>Listeria</i> -infected human macrophages," <u>Immunogenetics</u> 53:105-113 (2001)
	Stemple and Mahanthappa, "Neural stem cells are blasting off," <u>Neuron</u> 18:1-4 (1997)
	Treisman, "Inside the MADS box," <u>Nature</u> 376:468-469 (1995)
Ama	Tsunoda et al., "Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray," <u>Anticancer Res.</u> 21:137-143 (2001)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED <i>4/3/03</i>
------------------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-LJ 4714	SERIAL NO. 09/876,181
	APPLICANT: Lipton and Okamoto	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: June 5, 2001	GROUP 1646 1632

RECEIVED
DEC 27 2001
TECH CENTER 1600/2900

Ama	Uchida et al., "Direct isolation of human central nervous system stem cells," <u>Proc. Natl. Acad. Sci., USA</u> 97:14720-14725 (2000)
	Watson et al., "Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons," <u>J. Neurosci.</u> 18:751-762 (1998)
	Williams et al., "A PDGF-Regulated Immediate Early Gene Response Initiates Neuronal Differentiation in Ventricular Zone Progenitor Cells," <u>Neuron</u> 18:553-562 (1997)
	Wobus et al., "Embryonic Stem Cells and Nuclear Transfer Strategies," <u>Cells Tissues Organs</u> 166:1-5 (2000)
	Yang et al., "Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors," <u>Mol. Cell. Biol.</u> 19:4028-4038 (1999)
	Yin et al., "AC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells," <u>Blood</u> 90:5002-5012 (1997)
	Youn et al., "Apoptosis of T Cells Mediated by Ca ²⁺ -Induced Release of the Transcription Factor MEF2," <u>Science</u> 286:790-793 (1999)
	Yu et al., "Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors," <u>Genes & Dev.</u> 6:1783-1798 (1992)
✓	Zhao et al., "Regulation of the MEF2 family of transcription factors by p38," <u>Mol. Cell. Biol.</u> 19:21-30 (1999)
Ama	Zirlinger et al., "Amygdala-enriched genes identified by microarray technology are restricted to specific amygdaloid subnuclei," <u>Proc. Natl. Acad. Sci., USA</u> 98:5270-5275 (2001)

EXAMINER <i>Anne-Marie Falk</i>	DATE CONSIDERED <i>4/3/03</i>
------------------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.